Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NeuroOne Medical Technologies (NMTC)
NASDAQ:NMTC
RESEARCH TOOLSreports
Holding NMTC?
Track your performance easily
Earnings Data
Report Date
Feb 18, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.14Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Dec 15, 2021
|% Change Since: 51.32%
|Next Earnings Date:Aug 13, 2021
Earnings Call Sentiment|Positive
The call showcased significant achievements such as FDA clearance, strategic partnerships, and strong projected growth, but also highlighted challenges with current revenue decline and increased net losses. However, the focus on future growth and technological advancements provides a positive outlook.Company Guidance
During the NeuroOne Q4 2024 earnings call, the company outlined significant achievements and provided guidance for 2025. NeuroOne successfully received a 510(k) clearance for its OneRF ablation system, marking it as the first FDA-cleared device for both reporting electrical activity and ablating nervous tissue. The expanded partnership with Zimmer Biomet is expected to drive revenue growth, with projected fiscal year 2025 revenues between $8 million and $10 million, reflecting a 132% to 190% increase over 2024. Gross margins are anticipated to improve from 31% in 2024 to between 47% and 51% in 2025. Additionally, NeuroOne plans to submit an FDA application for trigeminal neuralgia in the first half of 2025, potentially contributing to revenue that year. The call highlighted the company's strategic focus on commercialization, product development, and financial objectives, aiming for accelerated revenue growth and margin improvement.FDA Clearance and Strategic Partnership
Achieved 510(k) clearance from the FDA for the OneRF ablation system and secured a strategic distribution partnership with Zimmer Biomet.
Projected Revenue Growth
Provided guidance for fiscal year 2025 revenue of $8 million to $10 million, representing growth of 132% to 190% over 2024.
Gross Margin Improvement
Projected gross margins for fiscal year 2025 to range between 47% and 51%, up from 31% in 2024.
Successful Initial Launch of OneRF System
Completed OneRF ablation procedures in 12 patients with significant reduction in seizures and strong physician interest.
Expanded Product Applications
Pursuing additional FDA submissions for facial pain and potential new markets such as lower back and knee pain.
---
NMTC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NMTC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Dec 17, 2024 | $0.76 | $0.79 | +3.95% |
| Aug 14, 2024 | $0.74 | $0.73 | -1.35% |
| May 14, 2024 | $1.14 | $1.06 | -7.02% |
| Feb 13, 2024 | $1.41 | $1.08 | -23.40% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does NeuroOne Medical Technologies (NMTC) report earnings?
NeuroOne Medical Technologies (NMTC) is schdueled to report earning on Feb 18, 2025, TBA Not Confirmed.
What is NeuroOne Medical Technologies (NMTC) earnings time?
NeuroOne Medical Technologies (NMTC) earnings time is at Feb 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NMTC EPS forecast?
Currently, no data Available
---